Bibliography
Found 48 results
Filters: Author is CHARTER Group [Clear All Filters]
Abdominal obesity contributes to neurocognitive impairment in HIV-infected patients with increased inflammation and immune activation. J Acquir Immune Defic Syndr. 2015 ;68(3):281-8.
Absence of neurocognitive effect of hepatitis C infection in HIV-coinfected people. Neurology. 2015 ;84(3):241-50.
Apolipoprotein E4 genotype does not increase risk of HIV-associated neurocognitive disorders. J Neurovirol. 2013 ;19(2):150-6.
Asymptomatic HIV-associated neurocognitive impairment increases risk for symptomatic decline. Neurology. 2014 ;82(23):2055-62.
Brain morphometric correlates of metabolic variables in HIV: the CHARTER study. J Neurovirol. 2014 ;20(6):603-11.
CD4 nadir is a predictor of HIV neurocognitive impairment in the era of combination antiretroviral therapy. AIDS. 2011 ;25(14):1747-51.
Clinical factors related to brain structure in HIV: the CHARTER study. J Neurovirol. 2011 ;17(3):248-57.
A concise panel of biomarkers identifies neurocognitive functioning changes in HIV-infected individuals. J Neuroimmune Pharmacol. 2013 ;8(5):1123-35.
. The concomitant use of second-generation antipsychotics and long-term antiretroviral therapy may be associated with increased cardiovascular risk. Psychiatry Res. 2014 ;218(1-2):201-8.
. Concurrent classification accuracy of the HIV dementia scale for HIV-associated neurocognitive disorders in the CHARTER Cohort. J Acquir Immune Defic Syndr. 2013 ;62(1):36-42.
Correlates of HIV RNA concentrations in cerebrospinal fluid during antiretroviral therapy: a longitudinal cohort study. Lancet HIV. 2019 ;6(7):e456-e462.
Efavirenz concentrations in CSF exceed IC50 for wild-type HIV. J Antimicrob Chemother. 2011 ;66(2):354-7.
Effects of traumatic brain injury on cognitive functioning and cerebral metabolites in HIV-infected individuals. J Clin Exp Neuropsychol. 2011 ;33(3):326-34.
Ethnic/Racial Disparities in Longitudinal Neurocognitive Decline in People With HIV. J Acquir Immune Defic Syndr. 2022 ;90(1):97-105.
Etravirine in CSF is highly protein bound. J Antimicrob Chemother. 2013 ;68(5):1161-8.
Genetic features of cerebrospinal fluid-derived subtype B HIV-1 tat. J Neurovirol. 2012 ;18(2):81-90.
Health-related quality of life 'well-being' in HIV distal neuropathic pain is more strongly associated with depression severity than with pain intensity. Psychosomatics. 2012 ;53(4):380-6.
HIV Distal Neuropathic Pain Is Associated with Smaller Ventral Posterior Cingulate Cortex. Pain Med. 2017 ;18(3):428-440.
HIV-associated distal neuropathic pain is associated with smaller total cerebral cortical gray matter. J Neurovirol. 2014 ;20(3):209-18.
HIV-associated neurocognitive disorders before and during the era of combination antiretroviral therapy: differences in rates, nature, and predictors. J Neurovirol. 2011 ;17(1):3-16.
HIV-associated neurocognitive disorders persist in the era of potent antiretroviral therapy: CHARTER Study. Neurology. 2010 ;75(23):2087-96.
Human immunodeficiency virus protease inhibitors and risk for peripheral neuropathy. Ann Neurol. 2008 ;64(5):566-72.
Increases in brain white matter abnormalities and subcortical gray matter are linked to CD4 recovery in HIV infection. J Neurovirol. 2013 ;19(4):393-401.
Long-term efavirenz use is associated with worse neurocognitive functioning in HIV-infected patients. J Neurovirol. 2016 ;22(2):170-8.